Bio-Rad Laboratories (NYSE:BIO.B) (NYSE: BIO.B) develops, manufactures and supplies products and services used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers, helping them analyze biological samples, conduct research and support diagnostic testing.
Its Life Science segment offers laboratory instruments, reagents, consumables and software for applications including polymerase chain reaction (PCR), digital PCR, droplet-based analysis, electrophoresis, chromatography, protein research, cell biology and gene expression. Bio-Rad also provides products used in food and beverage testing and other quality-control applications.
Through its Clinical Diagnostics segment, Bio-Rad supplies systems, reagents, controls and software for areas such as diabetes monitoring, infectious-disease testing, blood typing and immunohematology, quality control and autoimmune diagnostics. The company markets its products internationally through direct sales, distributors and service organizations.
Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California. Norman D. Schwartz has served as the company’s president and chief executive officer and is a member of the Schwartz family that has maintained a longstanding connection to the business.
